Collectively, this may not only improve a signature of decreased cancer cell stemness that alters the communicative nature of EMT with respect to down-modulated AGO2 expression of UA, but also provide clinicians with information on new applications in alternative effective therapeutic routes for breast cancer. The gene discussed is AGO2; the disease is breast carcinoma.